Management of hyperinflammation in COVID-19 patients

In response to SARS-CoV-2 infection, the immune system physiologically upregulates to try to clear the virus from the body; failure to compensate for this inflammatory response with an anti-inflammatory response leads to dysregulation of the immune system that ultimately leads to a situation of unco...

Full description

Saved in:
Bibliographic Details
Published in:Revista española de quimioterapia 2022-10, Vol.35 Suppl 3 (Suppl3), p.6-9
Main Authors: Suberviola, B, Cuenca Fito, E
Format: Article
Language:English
Subjects:
Anti-Inflammatory Agents - therapeutic use
Approach to management of SARS-CoV-2 infection
COVID-19 - complications
Cytokine Release Syndrome - drug therapy
Cytokine Release Syndrome - etiology
Cytokines
Humans
SARS-CoV-2
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c396t-abf196a7fa47106a101967b276d449a5cf179773007f1b14787be723f78b53aa3
cites
container_end_page 9
container_issue Suppl3
container_start_page 6
container_title Revista española de quimioterapia
container_volume 35 Suppl 3
creator Suberviola, B
Cuenca Fito, E
description In response to SARS-CoV-2 infection, the immune system physiologically upregulates to try to clear the virus from the body; failure to compensate for this inflammatory response with an anti-inflammatory response leads to dysregulation of the immune system that ultimately leads to a situation of uncontrolled hyperinflammation called cytokine storm. This cytokine storm can cause ARDS or multi-organ failure leading to patient death. This review exposes the different mechanisms of the inflammatory response in COVID-19 infection and the therapeutic options to treat this process.
doi_str_mv 10.37201/req/s03.02.2022
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9717453</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2729026098</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-abf196a7fa47106a101967b276d449a5cf179773007f1b14787be723f78b53aa3</originalsourceid><addsrcrecordid>eNpVkElPwzAQhS0EoqVw54Ry5JJ2vCSOL0iobJWKegGu1iS126Bs2ClS_z2GlgpOo5l5897oI-SSwphLBnTizMfEAx8DGzNg7IgMqcqyWCU0OyZDYFTEXDA1IGfevwMILhQ9JQOesizJhBoS8YwNrkxtmj5qbbTedsaVja2wrrEv2yYqm2i6eJvdxVRFXRgFoT8nJxYrby72dUReH-5fpk_xfPE4m97O44KrtI8xt1SlKC0KSSFFCqGVOZPpUgiFSWGpVFJyAGlpToXMZG4k41ZmecIR-Yjc7Hy7TV6bZRGyHVa6c2WNbqtbLPX_TVOu9ar91EpSKRIeDK73Bq792Bjf67r0hakqbEy78ZpJpoCloLIghZ20cK33zthDDAX9A1sH2DrA1sD0N-xwcvX3vcPBL13-BZq9ep8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2729026098</pqid></control><display><type>article</type><title>Management of hyperinflammation in COVID-19 patients</title><source>PubMed (Medline)</source><creator>Suberviola, B ; Cuenca Fito, E</creator><creatorcontrib>Suberviola, B ; Cuenca Fito, E</creatorcontrib><description>In response to SARS-CoV-2 infection, the immune system physiologically upregulates to try to clear the virus from the body; failure to compensate for this inflammatory response with an anti-inflammatory response leads to dysregulation of the immune system that ultimately leads to a situation of uncontrolled hyperinflammation called cytokine storm. This cytokine storm can cause ARDS or multi-organ failure leading to patient death. This review exposes the different mechanisms of the inflammatory response in COVID-19 infection and the therapeutic options to treat this process.</description><identifier>ISSN: 0214-3429</identifier><identifier>ISSN: 1988-9518</identifier><identifier>EISSN: 1988-9518</identifier><identifier>DOI: 10.37201/req/s03.02.2022</identifier><identifier>PMID: 36285849</identifier><language>eng</language><publisher>Spain: Sociedad Española de Quimioterapia</publisher><subject>Anti-Inflammatory Agents - therapeutic use ; Approach to management of SARS-CoV-2 infection ; COVID-19 - complications ; Cytokine Release Syndrome - drug therapy ; Cytokine Release Syndrome - etiology ; Cytokines ; Humans ; SARS-CoV-2</subject><ispartof>Revista española de quimioterapia, 2022-10, Vol.35 Suppl 3 (Suppl3), p.6-9</ispartof><rights>The Author 2022. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).</rights><rights>The Author 2022 2022</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-abf196a7fa47106a101967b276d449a5cf179773007f1b14787be723f78b53aa3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717453/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717453/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36285849$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suberviola, B</creatorcontrib><creatorcontrib>Cuenca Fito, E</creatorcontrib><title>Management of hyperinflammation in COVID-19 patients</title><title>Revista española de quimioterapia</title><addtitle>Rev Esp Quimioter</addtitle><description>In response to SARS-CoV-2 infection, the immune system physiologically upregulates to try to clear the virus from the body; failure to compensate for this inflammatory response with an anti-inflammatory response leads to dysregulation of the immune system that ultimately leads to a situation of uncontrolled hyperinflammation called cytokine storm. This cytokine storm can cause ARDS or multi-organ failure leading to patient death. This review exposes the different mechanisms of the inflammatory response in COVID-19 infection and the therapeutic options to treat this process.</description><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Approach to management of SARS-CoV-2 infection</subject><subject>COVID-19 - complications</subject><subject>Cytokine Release Syndrome - drug therapy</subject><subject>Cytokine Release Syndrome - etiology</subject><subject>Cytokines</subject><subject>Humans</subject><subject>SARS-CoV-2</subject><issn>0214-3429</issn><issn>1988-9518</issn><issn>1988-9518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVkElPwzAQhS0EoqVw54Ry5JJ2vCSOL0iobJWKegGu1iS126Bs2ClS_z2GlgpOo5l5897oI-SSwphLBnTizMfEAx8DGzNg7IgMqcqyWCU0OyZDYFTEXDA1IGfevwMILhQ9JQOesizJhBoS8YwNrkxtmj5qbbTedsaVja2wrrEv2yYqm2i6eJvdxVRFXRgFoT8nJxYrby72dUReH-5fpk_xfPE4m97O44KrtI8xt1SlKC0KSSFFCqGVOZPpUgiFSWGpVFJyAGlpToXMZG4k41ZmecIR-Yjc7Hy7TV6bZRGyHVa6c2WNbqtbLPX_TVOu9ar91EpSKRIeDK73Bq792Bjf67r0hakqbEy78ZpJpoCloLIghZ20cK33zthDDAX9A1sH2DrA1sD0N-xwcvX3vcPBL13-BZq9ep8</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Suberviola, B</creator><creator>Cuenca Fito, E</creator><general>Sociedad Española de Quimioterapia</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20221001</creationdate><title>Management of hyperinflammation in COVID-19 patients</title><author>Suberviola, B ; Cuenca Fito, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-abf196a7fa47106a101967b276d449a5cf179773007f1b14787be723f78b53aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Approach to management of SARS-CoV-2 infection</topic><topic>COVID-19 - complications</topic><topic>Cytokine Release Syndrome - drug therapy</topic><topic>Cytokine Release Syndrome - etiology</topic><topic>Cytokines</topic><topic>Humans</topic><topic>SARS-CoV-2</topic><toplevel>online_resources</toplevel><creatorcontrib>Suberviola, B</creatorcontrib><creatorcontrib>Cuenca Fito, E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Revista española de quimioterapia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suberviola, B</au><au>Cuenca Fito, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of hyperinflammation in COVID-19 patients</atitle><jtitle>Revista española de quimioterapia</jtitle><addtitle>Rev Esp Quimioter</addtitle><date>2022-10-01</date><risdate>2022</risdate><volume>35 Suppl 3</volume><issue>Suppl3</issue><spage>6</spage><epage>9</epage><pages>6-9</pages><issn>0214-3429</issn><issn>1988-9518</issn><eissn>1988-9518</eissn><abstract>In response to SARS-CoV-2 infection, the immune system physiologically upregulates to try to clear the virus from the body; failure to compensate for this inflammatory response with an anti-inflammatory response leads to dysregulation of the immune system that ultimately leads to a situation of uncontrolled hyperinflammation called cytokine storm. This cytokine storm can cause ARDS or multi-organ failure leading to patient death. This review exposes the different mechanisms of the inflammatory response in COVID-19 infection and the therapeutic options to treat this process.</abstract><cop>Spain</cop><pub>Sociedad Española de Quimioterapia</pub><pmid>36285849</pmid><doi>10.37201/req/s03.02.2022</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0214-3429
ispartof Revista española de quimioterapia, 2022-10, Vol.35 Suppl 3 (Suppl3), p.6-9
issn 0214-3429
1988-9518
1988-9518
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9717453
source PubMed (Medline)
subjects Anti-Inflammatory Agents - therapeutic use
Approach to management of SARS-CoV-2 infection
COVID-19 - complications
Cytokine Release Syndrome - drug therapy
Cytokine Release Syndrome - etiology
Cytokines
Humans
SARS-CoV-2
title Management of hyperinflammation in COVID-19 patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T03%3A38%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20hyperinflammation%20in%20COVID-19%20patients&rft.jtitle=Revista%20espa%C3%B1ola%20de%20quimioterapia&rft.au=Suberviola,%20B&rft.date=2022-10-01&rft.volume=35%20Suppl%203&rft.issue=Suppl3&rft.spage=6&rft.epage=9&rft.pages=6-9&rft.issn=0214-3429&rft.eissn=1988-9518&rft_id=info:doi/10.37201/req/s03.02.2022&rft_dat=%3Cproquest_pubme%3E2729026098%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c396t-abf196a7fa47106a101967b276d449a5cf179773007f1b14787be723f78b53aa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2729026098&rft_id=info:pmid/36285849&rfr_iscdi=true